StonvexLoading…
StonvexStonvexStonvexCore line items from RSG's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $4.11B | $16.59B | $12.46B | $8.24B |
Operating Income | $830.00M | $3.30B | $2.50B | $1.67B |
Net Income | $525.26M | $2.14B | $1.59B | $1.04B |
EPS (Diluted) | $1.70 | $6.85 | $5.10 | $3.33 |
Total Assets | $34.60B | $34.37B | $33.79B | $33.40B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $118.00M | $76.00M | $84.00M | $122.00M |
Free Cash Flow OCF − CapEx | $751.00M | $2.41B | $2.00B | $1.27B |
Shares Outstanding | 309.27M | 312.17M | 312.88M | 313.32M |